Details of the Drug Combinations

General Information of This Drug (ID: DM3JDRP)

• Drug Name: Cladribine (DM3JDRP)
• Synonyms: Chlorodeoxyadenosine; Cladarabine; Cladaribine; Cladribina; Cladribinum; CldAdo; Leustat; Leustatin; Litak; Movectro;Mylinax; CL9; RWJ 26251; Leustatin (TN); RWJ-26251; Cladribine [USAN:INN:BAN]; RWJ-26251-000; Cladribine (JAN/USAN/INN); Leustatin, 2-chlorodeoxyadenosine, Cladribine; Adenosine, 2-chloro-2'-deoxy; (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2 Chlorodeoxyadenosine; 2'-Deoxy-2-chloroadenosine; 2-CdA; 2-Chloro-2'-deoxy-beta-adenosine; 2-Chloro-2'-deoxyadenosine; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; 2-Chlorodeoxyadenosine; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; 2-chloro-deoxyadenosine

Indication

Hairy cell leukaemia; ICD 11: 2A82.2; Status: Approved [1]; Multiple sclerosis; ICD 11: 8A40; Status: Phase 3 [2]; Relapsing-remitting multiple sclerosis; ICD 11: 8A40.0; Status: Phase 3 [3]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

14 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ABT-263 + Cladribine	DCLP3U5	ABT-263	Glioblastoma (Cell Line: JHH-136)	[4]
AZD8055 + Cladribine	DCR95QJ	AZD8055	Glioblastoma (Cell Line: JHH-136)	[5]
BIIB-021 + Cladribine	DCCE2RM	BIIB-021	Glioblastoma (Cell Line: JHH-136)	[5]
CA4P + Cladribine	DCPK56Z	CA4P	Glioblastoma (Cell Line: JHH-136)	[5]
Cladribine + Trametinib	DCTS3Z4	Trametinib	Glioblastoma (Cell Line: JHH-136)	[5]
Cladribine + Cladribine	DCCEDU6	Cladribine	Glioblastoma (Cell Line: JHH-136)	[5]
Cladribine + Ixazomib	DC1JUOP	Ixazomib	Glioblastoma (Cell Line: JHH-136)	[5]
Cladribine + Marizomib	DCBVOWG	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Cladribine + Idarubicin	DCCOL2D	Idarubicin	Glioblastoma? (Cell Line: T98G)	[5]
Cladribine + GSK2126458	DCBZFIH	GSK2126458	Glioblastoma (Cell Line: JHH-136)	[5]
Cladribine + Obatoclax	DC6HBJI	Obatoclax	Glioblastoma (Cell Line: JHH-136)	[5]
Fenretinide + Cladribine	DCTKFH5	Fenretinide	Glioblastoma (Cell Line: JHH-136)	[5]
Pelitinib + Cladribine	DC5SCNS	Pelitinib	Glioblastoma (Cell Line: JHH-136)	[5]
TAK-733 + Cladribine	DCM886U	TAK-733	Glioblastoma (Cell Line: JHH-136)	[5]

12 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Cladribine + Idarubicin	DC2CYI3	Idarubicin	Leukemia	[6]
Cladribine + Pantoprazole	DC7S69E	Pantoprazole	Multiple Sclerosis	[7]
Cladribine + Vorinostat	DCKSYUJ	Vorinostat	Recurrent B-Cell Non-Hodgkin Lymphoma	[8]
Cladribine + Temsirolimus	DCNYKD4	Temsirolimus	Lymphoma	[9]
Cladribine + Mitoxantrone	DCV2945	Mitoxantrone	Acute Lymphoblastic Leukemia	[10]
Cladribine + INCB24360	DCLMC3G	INCB24360	AML	[11]
Selinexor + Cladribine	DC7CTPG	Selinexor	Acute Myeloid Leukemia	[12]
Cladribine + Venetoclax	DC5SGO6	Venetoclax	Acute Myeloid Leukemia	[13]
Cladribine + Decitabine	DCVCUPT	Decitabine	Acute Myeloid Leukemia	[14]
Cladribine + Vemurafenib	DCW1O6P	Vemurafenib	Langerhans Cell Histiocytosis	[15]
Cladribine + Venetoclax	DCSF8IM	Venetoclax	Acute Myeloid Leukemia	[13]
Cladribine + Busulfan	DCRF4SL	Busulfan	High Risk Acute Myeloid Leukemia	[16]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4799).
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [5] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [6] ClinicalTrials.gov (NCT00003178) Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia
• [7] ClinicalTrials.gov (NCT00938366) Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects
• [8] ClinicalTrials.gov (NCT00764517) Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma
• [9] ClinicalTrials.gov (NCT00787969) Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
• [10] ClinicalTrials.gov (NCT01513603) Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
• [11] ClinicalTrials.gov (NCT03491579) Epacadostat, Cladribine and Cytarabine (ECC) in AML
• [12] ClinicalTrials.gov (NCT02416908) Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
• [13] ClinicalTrials.gov (NCT06232655) Cladribine Venetoclax in Monocytic AML
• [14] ClinicalTrials.gov (NCT05766514) Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
• [15] ClinicalTrials.gov (NCT03585686) A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation
• [16] ClinicalTrials.gov (NCT03384212) CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML